Modern Biopharmaceuticals
Design, Development and Optimization
(Sprache: Englisch)
Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
Fr. 1037.90
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Modern Biopharmaceuticals “
Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R.
Klappentext zu „Modern Biopharmaceuticals “
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.
With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.
Inhaltsverzeichnis zu „Modern Biopharmaceuticals “
Volume 1: Molecular Medicine and Protein EngineeringMODERN BIOPHARMACEUTICALS
- Setting the tone: preface from Nobelprize Laureate Prof. R. Huber
- History, current and future: definition & scope - where do we come from and where will we go
MOLECULAR MEDICINE
SNPs analysis: general ethical aspects and the Estonian Genome Project
- Individualized medicine: benefits, challenges and the healthcare sector - interdependencies
- Genomics-based biopharmaceuticals: turning the genome into drugs
- Gene therapy and retro elements for construction of sophisticated vectors
- Gene pill: harnessing the body's protein production
- Adenovirus-based gene therapy entering phase III
- Genetic vaccination as prevention against AIDS, hepatitis and cancer
- Cell therapy: spheramine - a brain implant for treating Parkinson's disease
- Fighting cancer by selectively starving the cells
- Knock-out mice as disease models and to discover true physiological gene functions
PROTEIN DESIGN
- Enzyme optimization: modifying selectivity, stability, kinetics and characteristics
- Combining tailored in vitro selection strategies based on ribosome display with in vitro diversification by DNA shuffling
- Antibody design: improved stability and other pharm. properties of different formats
- Humization of antibodies and reduced immunogenicity (e.g. elimination of HAMA)
- Phage display: design of monoclonal antibodies, increasing selectivity and affinity
- Generating muteins: increasing biological activity and solubility
PROTEIN EXPRESSION
- Different alternative expression systems (e.g. Dictyostelium): pros & cons
- Humanized mouse cell line: human gylcosylation combined with high protein expression. G-line is a human-mouse heterohybridoma cell line
- Advanced mammalian (CHO, HEK, 293, BHK, 3T3) expression: Flp-In, T-REx
- Plant systems I: easy downstream - secretion of biopharmaceutical via the roots and high yields with viral vectors
- Plant systems II: human
... mehr
glycosylation - biopharmaceuticals in a GMP moss bioreactor
- Volume 2 Drug Development
FROM SYSTEMIC TO TARGETED APPROACH
- Target specific diagnostics & therapeutics: radiopharmaceuticals - find, fight, follow
- Ligand-based in vivo targeting of disease: from antibody to small organic ligands
- PET imaging: the magic bullet to study cancer and metabolism in real time
- Advanced Drug Delivery Systems
HIGH THROUGHPUT CLONING
- Massive parallel expression of biopharmaceuticals for screening purposes
- Learning from viruses: easy cloning without restriction enzymes (e.g. Gateway)
IN VIVO AND IN VITRO ANALYTICAL METHODS
- Cell-based assays (e.g. GFP)
- Pharmacodynamic / pharmacokinetic, efficacy, side effects and interactions
- IVIV correlation
DOMAIN EXCHANGE BY SHUFFLING AND SWAPPING
- Improving enzymes: Taq Polymerases with proof reading activity etc.
- Metabolic engineering: domain exchange in Polyketide Synthases and how to create new unnatural & complex natural compounds (heterocyclic systems, e.g. epothilon)
CASE STUDY
- Design & approval: Baxter's R&D activities with Recombinate, AntiHemophilic Factor (rAHF) as clotting Factor VIII - essential for more than 300,000 people suffering from hemophilia. History of product development, approval, expansion of production capacities (begin of construction in 1992 until licensing in 1996)
ADVANTAGES OF SMALL MOLECULES
- Back to the past or ahead of the future: in silico ADME predictions class switching from peptide to small molecule lead candidates
ARE INNOVATIVE DRUGS STILL PAYABLE?
- Economical aspects of modern biopharmaceuticals. R&D management in the biotech industry - facing regional challenges and impact of changes in the health systems
- Volume 2 Drug Development
FROM SYSTEMIC TO TARGETED APPROACH
- Target specific diagnostics & therapeutics: radiopharmaceuticals - find, fight, follow
- Ligand-based in vivo targeting of disease: from antibody to small organic ligands
- PET imaging: the magic bullet to study cancer and metabolism in real time
- Advanced Drug Delivery Systems
HIGH THROUGHPUT CLONING
- Massive parallel expression of biopharmaceuticals for screening purposes
- Learning from viruses: easy cloning without restriction enzymes (e.g. Gateway)
IN VIVO AND IN VITRO ANALYTICAL METHODS
- Cell-based assays (e.g. GFP)
- Pharmacodynamic / pharmacokinetic, efficacy, side effects and interactions
- IVIV correlation
DOMAIN EXCHANGE BY SHUFFLING AND SWAPPING
- Improving enzymes: Taq Polymerases with proof reading activity etc.
- Metabolic engineering: domain exchange in Polyketide Synthases and how to create new unnatural & complex natural compounds (heterocyclic systems, e.g. epothilon)
CASE STUDY
- Design & approval: Baxter's R&D activities with Recombinate, AntiHemophilic Factor (rAHF) as clotting Factor VIII - essential for more than 300,000 people suffering from hemophilia. History of product development, approval, expansion of production capacities (begin of construction in 1992 until licensing in 1996)
ADVANTAGES OF SMALL MOLECULES
- Back to the past or ahead of the future: in silico ADME predictions class switching from peptide to small molecule lead candidates
ARE INNOVATIVE DRUGS STILL PAYABLE?
- Economical aspects of modern biopharmaceuticals. R&D management in the biotech industry - facing regional challenges and impact of changes in the health systems
... weniger
Autoren-Porträt
Dr. Jörg Knäblein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest
Bibliographische Angaben
- 2005, 1. Auflage, CXXXVI, 1886 Seiten, 124 farbige Abbildungen, 377 Schwarz-Weiss-Abbildungen, Masse: 24 cm, Gebunden, Englisch
- Herausgegeben: Jörg Knäblein, Rainer H. Müller
- Verlag: Wiley-VCH
- ISBN-10: 352731184X
- ISBN-13: 9783527311842
Sprache:
Englisch
Rezension zu „Modern Biopharmaceuticals “
"Der Herausgeber Dr. Jörg Knäblein ist der Leiter der Abteilung Mikrobiologische Chemie bei Schering. Das Werk ist eine einzigartige und umfassende Einführung in die neuere technologische Entwicklung bei Biopharmazeutika, es zeigt die Paradigmenwechsel in der medizinischen Behandlung auf und wie diese Veränderungen auf die industrielle Forschung ausstrahlen. Die Autoren des Werkes kommen aus den weltweit renommiertesten Forschungsinstituten - darunter die Nobelpreisträger Robert Huber und Thomas R. Cech - und Biotechnologie-Unternehmen." CHEManager"Das Werk umfasst vier Bände mit allein 80-seitigem Executive Summary. Hier wird das heutige Wissen der modernen Wirkstoffentwicklung aus akademischer und Industrieforschung zusammengeführt. Von Antikörper bis Zulassungsverfahren: Methoden, Mechanismen, Genregulation und Gesundheitspolitik werden von ausgewiesenen Spezialisten detailliert auf dem neuesten Stand dargestellt." BioRegioN"...ein umfassendes Bild über den aktuellen Stand derbiotechnologischen Entwicklung auf der Basis molekularbiologischer Wissenschaften... Die beigefügte CD zum Buch enthält unter anderem einige beeindruckende Darstellungen aus dem Institut von Dr. Hwang ... Ebenfalls sind die kompletten Inhaltsverzeichnisse in jedem Band hilfreich. ... molekularbiologische Strukturen und Abbildungen in hoher Qualität ... Ein umfassendes Werk und Spiegel der derzeit erfolgreichen Pharma-Branche." Umwelt und Gesundheit "Vier Bände, 1886 Seiten, 4,5 Kilogramm Lebendgewicht: "Modern Biopharmaceuticals" beansprucht, rein optisch gesehen, viel Platz. Inhaltlich ist damit der Anspruch auf Vollständigkeit verbunden. In der Tat decken die Beiträge ein extrem breites Themenspektrum ab, das seinesgleichen sucht...Nicht nur inhaltlich, sondern auch unter formalen Gesichtspunkten kann das Buch punkten. Die einzelnen Kapitel illustrieren die Themen teilweise an instruktiven Fallbeispielen und sind im Detail präzise, ohne sich in Nebensächlichkeiten zu verlieren...
... mehr
Unternehmen, Organisationen und Behörden, die sich im weitesten Sinne mit Biotechnologie und Biopharmazeutika befassen ... investieren sinnvoll ..." Nachrichten aus der Chemie"Ein wirklich beeindruckendes Werk. Wenn man sich über Wochen mit den vier Bänden beschäftigt und dazu noch die eindrucksvollen Präsentationen und Filme der beiliegenden CD angesehen hat, kommt man zu dem Schluss, dass die zu Beginn zitierten Marketingaussagen absolut zutreffend sind. Dieses Werk ist ein "Guiness Buch" der Biotechnologie, von der ersten bis zur letzten Seite spannend und lehrreich, geeignet für den Studenten wie für den Dozenten, für den Grundlagenforscher wie für den Entwickler. Mit nahezu 400 Graphiken gut bebildert, bleibt neben der hohen Informationsdichte auch immer Platz für die didaktischen Ansätze. Es ist zu hoffen und zu erwarten, dass diese vier Bände über Design, Entwicklung und Optimierung von modernen biopharmazeutischen Produkten in den wissenschaftlichen Instituten und den Büros der pharmazeutischen und biotechnologischen Industrie Einzug halten werden."Arzneimittel-Forschung / Drug Research"Dem Herausgeber ist mit diesem Werk gelungen, das gesamte Spektrum der Biopharmazeutika umfassend abzudecken, weshalb man heute vom "Guiness-Buch der Biotechnologie" spricht."Pharmazie in unserer Zeit
... weniger
Pressezitat
"... an authoritative sourcebook dealing with the entire broad range of biopharmaceuticals now available. ... an impressive compilation of outstanding results written by brilliant, creative thinkers who are shaping present and future biotechnology. I am pleased to recommend strongly this complete and comprehensive basic reference source for this new, exciting field to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists, and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should also be invaluable to undergraduate and graduate students, postdoctoral fellows, and researchers looking for quick, clear, and concise ideas on topics that lie outside their areas of expertise. It also belongs in academic, industrial, and governmental libraries."The Chemical Educator
"This is an extensive and unmatched compilation of comprehensive, in-depth current knowledge and history of biopharmaceuticals...the author is commended for this grand effort." Veterinary Pathology
"I heartly recommend this authoritative, comprehensive reference to this new, exciting field dealing with the entire broad range of available biopharmaceuticals. It will be invaluable to biotechnologists, clinicians, physicians, pharmacists, pharmaceutical chemists, molecular biologists, medicinal chemists and anyone working in the biotechnological and pharmaceutical industries or in medicinal institutes. It should be also be useful for undergraduate and graduate students, postdoctoral fellows, and researchers seeking quick, clear, and concise ideas on topics outside their areas of specialization. it should also find a place in academic, industrial, and governmental libraries."
ChemMedChem
"All in all, this is an impressive snapshot of the field." Journal of Medicinal Chemistry
"... the four volumes represent a highly valuable reference compendium for any
... mehr
practicing scientists interested in this sector of biotechnology."
Chemistry and Industry
"Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies." BIOforum Europe
Chemistry and Industry
"Due to the impressive accumulation of outstanding results, presented by brilliant, privileged and creative thinkers, the book reads like the Who is Who of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies." BIOforum Europe
... weniger
Kommentar zu "Modern Biopharmaceuticals"
0 Gebrauchte Artikel zu „Modern Biopharmaceuticals“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
5 von 5 Sternen
5 Sterne 1Schreiben Sie einen Kommentar zu "Modern Biopharmaceuticals".
Kommentar verfassen